Patients on glucagon-like peptide 1 (GLP-1) receptor agonists (p = 0.018) and sodium-glucose cotransporter-2 (SGLT2) inhibitors (p = 0.042) had a significantly lower prevalence of NAFLD. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.